Kezar Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Kezar Life Sciences's estimated annual revenue is currently $10.5M per year.
- Kezar Life Sciences's estimated revenue per employee is $119,773
- Kezar Life Sciences's total funding is $123M.
- Kezar Life Sciences's current valuation is $755.4M. (January 2022)
Employee Data
- Kezar Life Sciences has 88 Employees.
- Kezar Life Sciences grew their employee count by 60% last year.
Kezar Life Sciences's People
| Name | Title | Email/Phone |
|---|
Kezar Life Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $750M | 4907 | -3% | $149.1M | N/A |
What Is Kezar Life Sciences?
We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.
keywords:N/A
$123M
Total Funding
88
Number of Employees
$10.5M
Revenue (est)
60%
Employee Growth %
$755.4M
Valuation
N/A
Accelerator
Kezar Life Sciences News
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics...
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and...
Herrero Builders Inc. Hirsch Philanthropy Partners Hotel Nikko San Francisco Intercom Johanson & Yau Joseph J. Albanese, Inc. Kezar Life Sciences Lively
Kezar Life Sciences, a South San Francisco, Calif.-based clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, closed a $50m Series B funding. The round was led by Cormorant Asset Management and Mo ...
Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, announced today that it has closed an oversubscribed Series B investment round of $50 million led by Cormorant A ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $28.6M | 88 | -4% | N/A |
#2 | $12.8M | 88 | -8% | N/A |
#3 | $12.8M | 88 | N/A | N/A |
#4 | $12.8M | 88 | N/A | N/A |
#5 | $17.8M | 88 | -11% | $20M |